HR Execs on the Move

Amedica Corporation

www.amedicacorp.com

 
Only Amedica has developed the technology to create medical grade silicon nitride ceramic; a material that, compared to others on the market, promises spinal implants with excellent osteoconductive properties, higher wear resistance, and greatly improved compatibility with MRI, fluoroscopy and CT imaging systems.  
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Femasys

Our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. The pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. The team is complemented by world-class medical advisors. Our products have been organically conceived, researched and developed by the Company and all manufacturing activities are conducted to ensure compliance with the U.S. Food and Drug Administration (FDA) per the requirements of 21 CFR 820, as well as ISO 13485. Femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the U.S. Food and Drug Administration (FDA), European Union, Canada, and Japan with other select countries in process. Making a difference in the lives of women one product at a time is a great privilege and serves to drive the Company`s mission.

A C Adderson Healthcare Inc

A C Adderson Healthcare Inc is a Corona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Luminex Corporation

Luminex Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

IBP MEDICAL

IBP MEDICAL is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Specific Diagnostics

Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Revealâ„¢ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific`s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.